FI20030379A0 - Uusi farmaseuttinen koostumus - Google Patents

Uusi farmaseuttinen koostumus

Info

Publication number
FI20030379A0
FI20030379A0 FI20030379A FI20030379A FI20030379A0 FI 20030379 A0 FI20030379 A0 FI 20030379A0 FI 20030379 A FI20030379 A FI 20030379A FI 20030379 A FI20030379 A FI 20030379A FI 20030379 A0 FI20030379 A0 FI 20030379A0
Authority
FI
Finland
Prior art keywords
pharmaceutical composition
agent
new pharmaceutical
animal
person
Prior art date
Application number
FI20030379A
Other languages
English (en)
Swedish (sv)
Inventor
Lasse Leino
Jarmo Laihia
Original Assignee
Lasse Leino
Jarmo Laihia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lasse Leino, Jarmo Laihia filed Critical Lasse Leino
Priority to FI20030379A priority Critical patent/FI20030379A0/fi
Publication of FI20030379A0 publication Critical patent/FI20030379A0/fi
Priority to DE602004011906T priority patent/DE602004011906T2/de
Priority to AU2004218944A priority patent/AU2004218944B2/en
Priority to EP08001152A priority patent/EP2014289A1/en
Priority to CA2518885A priority patent/CA2518885C/en
Priority to DK04715921T priority patent/DK1603559T3/da
Priority to ES04715921T priority patent/ES2299823T3/es
Priority to PCT/FI2004/000109 priority patent/WO2004080456A1/en
Priority to US10/534,988 priority patent/US8313738B2/en
Priority to PL04715921T priority patent/PL1603559T3/pl
Priority to AT04715921T priority patent/ATE386515T1/de
Priority to PT04715921T priority patent/PT1603559E/pt
Priority to SI200430650T priority patent/SI1603559T1/sl
Priority to JP2006505614A priority patent/JP5398954B2/ja
Priority to EP04715921A priority patent/EP1603559B1/en
Priority to CY20081100320T priority patent/CY1107346T1/el
Priority to JP2010285098A priority patent/JP2011057708A/ja
Priority to US13/584,999 priority patent/US8673281B2/en
Priority to US13/651,555 priority patent/US8673280B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Rheumatology (AREA)
  • Surgery (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FI20030379A 2003-03-14 2003-03-14 Uusi farmaseuttinen koostumus FI20030379A0 (fi)

Priority Applications (19)

Application Number Priority Date Filing Date Title
FI20030379A FI20030379A0 (fi) 2003-03-14 2003-03-14 Uusi farmaseuttinen koostumus
EP04715921A EP1603559B1 (en) 2003-03-14 2004-03-01 Pharmaceutical composition for intracellular acidification with cis-urocanic acid
US10/534,988 US8313738B2 (en) 2003-03-14 2004-03-01 Pharmaceutical composition for intracellular acidification with cis-urocanic acid
AT04715921T ATE386515T1 (de) 2003-03-14 2004-03-01 Pharmazeutische zusammensetzung für die intrazelluläre ansäuerung mit cis-urocansäure
EP08001152A EP2014289A1 (en) 2003-03-14 2004-03-01 Pharmaceutical composition for intracellular acidification with cis-urocanid acid
CA2518885A CA2518885C (en) 2003-03-14 2004-03-01 Pharmaceutical composition for intracellular acidification with cis-urocanic
DK04715921T DK1603559T3 (da) 2003-03-14 2004-03-01 Farmaceutisk sammensætning til intracellulær forsuring med cis-urocan
ES04715921T ES2299823T3 (es) 2003-03-14 2004-03-01 Composicion farmaceutica para acidificacion intracelular con acido cis-urocanico.
PCT/FI2004/000109 WO2004080456A1 (en) 2003-03-14 2004-03-01 Pharmaceutical composition for intracellular acidification with cis-urocanic
DE602004011906T DE602004011906T2 (de) 2003-03-14 2004-03-01 Pharmazeutische zusammensetzung für die intrazelluläre ansäuerung mit cis-urocansäure
PL04715921T PL1603559T3 (pl) 2003-03-14 2004-03-01 Kompozycja farmaceutyczna do wewnątrzkomórkowego zakwaszania kwasem cis-urokanowym
AU2004218944A AU2004218944B2 (en) 2003-03-14 2004-03-01 Pharmaceutical composition for intracellular acidification with cis-urocanic
PT04715921T PT1603559E (pt) 2003-03-14 2004-03-01 Composição farmacêutica para acidificação intracelular com cis-urocânico
SI200430650T SI1603559T1 (sl) 2003-03-14 2004-03-01 Farmacevtski sestavek za intracelularno nakisanjes cis-urokansko kislino
JP2006505614A JP5398954B2 (ja) 2003-03-14 2004-03-01 シス−ウロカニン酸を用いた細胞内酸性化のための医薬組成物
CY20081100320T CY1107346T1 (el) 2003-03-14 2008-03-21 Φαρμακευτικη συνθεση για την ενδοκυτταρια οξινιση με cis-ουροκανικο οξυ
JP2010285098A JP2011057708A (ja) 2003-03-14 2010-12-21 シス−ウロカニン酸を用いた細胞内酸性化のための医薬組成物
US13/584,999 US8673281B2 (en) 2003-03-14 2012-08-14 Pharmaceutical composition for intracellular acidification with cis-urocanic acid
US13/651,555 US8673280B2 (en) 2003-03-14 2012-10-15 Pharmaceutical composition for intracellar acidification with cis-urocanic acid

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI20030379A FI20030379A0 (fi) 2003-03-14 2003-03-14 Uusi farmaseuttinen koostumus

Publications (1)

Publication Number Publication Date
FI20030379A0 true FI20030379A0 (fi) 2003-03-14

Family

ID=8565804

Family Applications (1)

Application Number Title Priority Date Filing Date
FI20030379A FI20030379A0 (fi) 2003-03-14 2003-03-14 Uusi farmaseuttinen koostumus

Country Status (14)

Country Link
US (3) US8313738B2 (fi)
EP (2) EP1603559B1 (fi)
JP (2) JP5398954B2 (fi)
AT (1) ATE386515T1 (fi)
AU (1) AU2004218944B2 (fi)
CA (1) CA2518885C (fi)
CY (1) CY1107346T1 (fi)
DE (1) DE602004011906T2 (fi)
DK (1) DK1603559T3 (fi)
ES (1) ES2299823T3 (fi)
FI (1) FI20030379A0 (fi)
PL (1) PL1603559T3 (fi)
PT (1) PT1603559E (fi)
WO (1) WO2004080456A1 (fi)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI20031793A0 (fi) * 2003-12-09 2003-12-09 Lasse Leino Uusi anti-proliferatiivinen farmaseuttinen koostumus
JP5756615B2 (ja) * 2010-11-02 2015-07-29 花王株式会社 オートインデューサー−２阻害剤、並びに歯周病又は齲蝕病の予防及び／又は治療剤
WO2021181711A1 (ja) * 2020-03-10 2021-09-16 均 石井 アレルギー治療薬

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3876765A (en) * 1968-05-03 1975-04-08 Choay Sa Pharmaceutical composition containing vitamin b' 12', process of making the same and method of treatment therewith
JPS59139315A (ja) * 1983-01-31 1984-08-10 Taisho Pharmaceut Co Ltd クリ−ム剤
US5455036A (en) 1990-06-29 1995-10-03 Bode Chemie Method of using cis-urocaninic acid for topically treating psoriasis
DE4121030A1 (de) 1990-06-29 1992-01-02 Beiersdorf Ag Dermatologische zusammensetzungen mit einem gehalt an cis-urocaninsaeure
DE4122497C2 (de) * 1991-07-02 1998-03-26 Wogepharm Gmbh Verwendung von trans-Urokaninsäure bei der prophylaktischen Therapie der Psoriasis
US5843979A (en) * 1993-02-25 1998-12-01 Bristol-Myers Squibb Company Transdermal treatment with mast cell degranulating agents for drug-induced hypersensitivity
CA2114968A1 (en) 1993-02-25 1994-08-26 John Wille Transdermal treatment with mast cell degranulating agents for drug-induced hypersensitivity
GB9306473D0 (en) * 1993-03-29 1993-05-19 Bioglan Lab Ltd Pharmaceutically useful compounds
US5686100A (en) * 1994-11-22 1997-11-11 E.R. Squibb & Sons, Inc. Prophylactic and therapeutic treatment of skin sensitization and irritation
US6153176A (en) * 1995-01-20 2000-11-28 The Procter & Gamble Company Low pH sunscreen compositions
AU3309097A (en) * 1996-06-12 1998-01-07 Alza Corporation Reduction of skin sensitization in electrotransport drug delivery
CA2319060A1 (en) * 1998-02-05 1999-08-12 Senju Pharmaceutical Co., Ltd. Urocanic acid derivatives
DE19817295A1 (de) * 1998-04-18 1999-10-21 Beiersdorf Ag Kosmetische oder dermatologische Zubereitungen mit einem Gehalt an unsymmetrisch substituiertenTriazinderivaten zum Erhalt des Urocaninsäurestatus der Haut
US6420378B1 (en) * 1999-10-15 2002-07-16 Supergen, Inc. Inhibition of abnormal cell proliferation with camptothecin and combinations including the same
US6582734B1 (en) * 2000-07-20 2003-06-24 Ecolab Inc. Antimicrobial composition useful for the treatment of bovine mastitis
FI20031793A0 (fi) * 2003-12-09 2003-12-09 Lasse Leino Uusi anti-proliferatiivinen farmaseuttinen koostumus

Also Published As

Publication number Publication date
ATE386515T1 (de) 2008-03-15
JP2011057708A (ja) 2011-03-24
JP2006520369A (ja) 2006-09-07
ES2299823T3 (es) 2008-06-01
PT1603559E (pt) 2008-03-11
EP2014289A1 (en) 2009-01-14
PL1603559T3 (pl) 2008-07-31
US20130041006A1 (en) 2013-02-14
EP1603559B1 (en) 2008-02-20
US20060035973A1 (en) 2006-02-16
US8673281B2 (en) 2014-03-18
CY1107346T1 (el) 2012-12-19
JP5398954B2 (ja) 2014-01-29
DE602004011906T2 (de) 2009-02-26
US8673280B2 (en) 2014-03-18
EP1603559A1 (en) 2005-12-14
US8313738B2 (en) 2012-11-20
CA2518885A1 (en) 2004-09-23
AU2004218944A1 (en) 2004-09-23
US20120315299A1 (en) 2012-12-13
DK1603559T3 (da) 2008-06-23
DE602004011906D1 (de) 2008-04-03
AU2004218944B2 (en) 2009-10-08
CA2518885C (en) 2011-08-02
WO2004080456A1 (en) 2004-09-23

Similar Documents

Publication Publication Date Title
EA200101156A1 (ru) ЛЕКАРСТВЕННЫЕ КОМПОЗИЦИИ НОВОГО ТИПА НА ОСНОВЕ ОБЛАДАЮЩИХ ХОЛИНЕРГИЧЕСКИМ ДЕЙСТВИЕМ СОЕДИНЕНИЙ И β-МИМЕТИКОВ
BR0311313A (pt) Derivados de diaril uréia úteis para o tratamento de doenças dependentes de proteìna cinase
TR200002786T2 (tr) Meloksikam için yeni galenik bir formülasyon.
DE60126980D1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
BR9406363A (pt) Composiçao farmacêutica processo para a preparaçao da mesma uso da mesma e processo para o tratamento de doenças relacionadas com o ácido gástrico
UY27755A1 (es) Nuevas composiciones farmacéuticas basadas en anticolinérgicos e inhibidores.
DOP2002000429A (es) Imidazotriazinas
GEP20074123B (en) Amino acids with affinity for the alpha−2−delta−protein
DE60315479D1 (de) Pyrimidinamid derivate und deren verwendung
ATE260650T1 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
DE60016460D1 (de) Verwendungen und zusammenstellungen von nitratestern als sedativa
SE9802208D0 (sv) Novel compounds
HUP9602498A2 (hu) Antimikrobiális hatású gyógyászati készítmények
BR0210912A (pt) Compostos e composições como inibidores de catepsina
ITMI20022394A1 (it) Uso di triiodotironina 3-solfato come farmaco ad attivita' tireomimetica e relative formulazioni farmaceutiche.
ATE369348T1 (de) Zyklisierte benzamid-neurokinin-antagonisten zur verwendung in therapie
DE60137069D1 (de) Arzneizusammensetzungen enthaltend modafinilverbindungen
NO20051261L (no) Morfin-6-glukuronidsalt
PL350568A1 (en) N-(2-phenyl-4-aminobutyl)-1-naphtamides as antagonists of neurokinin 1 receptors
CY1107346T1 (el) Φαρμακευτικη συνθεση για την ενδοκυτταρια οξινιση με cis-ουροκανικο οξυ
BR0309996A (pt) Composto, composição farmacêutica, método de tratar ou melhorar doenças ou condições proliferativas, uso de um composto, e, método de tratar ou melhorar doenças inflamatórias
SE9802209D0 (sv) Novel compounds
SE0001916D0 (sv) Novel formulation
DE69635806D1 (de) Diphosphonat derivate von therapeutisch wirksamen stoffen
SE0000303D0 (sv) Novel compounds